Publication | Open Access

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung Cancer